JPMA, PhRMA and EFPIA: Joint Statement on FY2023 NHI Price Revisions
December 21, 2022
Japan Pharmaceutical Manufacturers Association
- Global Health
- Activities
- International Affairs Committee(Asia Committee)
- Deliverables of Drug Evaluation Committee
- Quality & Technology Committee
- JPMA Statement on WTO TRIPS Intellectual Property Waiver
- UN Climate Change Conference (COP26): Biopharmaceutical Industry Actions to Tackle Climate Change
- Three priorities to urgently increase access to COVID-19 vaccines
- Statement by JPMA President on the Passing of Former Prime Minister ABE Shinzo
- Opinion on Access and Benefit Sharing of Digital Sequence Information
- The“JAPANESE CONSENSUS FRAMEWORK FOR ETHICAL COLLABORATION" received the "2023 The Lighthouse Award" for its activities.
- Innovative pharmaceutical industry statement on COP28 Declaration on Climate and Health
- Code
- About Us
- ICH Project
- News Room